Overview

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Status:
Unknown status

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and effectiveness of Sintilimab Combined With Docetaxel in Non-driver Gene Mutation NSCLC patients who failed with double platinum-based chemotherapy

Phase:

Phase 2

Details

Lead Sponsor:

Yongchang Zhang

Treatments:

Docetaxel